DIA 2015 Annual Meeting, Washington, D.C. and Boston, Mass. – June 16, 2015 –BBK Worldwide, a leading clinical trial marketing firm, has appointed Toshio Mori to Managing Director of Operations, Japan. Mori will lead business development and help drive sales and marketing in Japan, and will report to BBK Principal, Global Resources Steven Fleishman. Mori is also responsible for establishing and growing the company’s new Japan office, based in Tokyo.
Mori brings more than 25 years of pharmaceutical and medical device experience to the role. Before BBK, Mori established and then led operations at Japan-based Candela KK, a subsidiary of Syneron-Candela, a global market leader in the aesthetic medical device marketplace. Earlier in his career, he held senior sales and marketing positions at Sansui Electronic Co.
“Toshio’s expertise across a broad set of disease areas – from cancer to neurological disorders – combined with his established leadership among physicians and study investigators will help us further extend our global reach and support the increased demand for clinical research in Japan,” said Fleishman. “We remain committed to expanding our support in Japan, and are happy to be entering this new phase of growth with Toshio’s support.”
“I was drawn to BBK for its leadership in patent recruitment and engagement, as well as its commitment to patient centricity and diversity,” said Mori. “I’m pleased to be joining the distinguished team and look forward to advancing the company’s work in Japan.”
With deep experience across many multinational patient recruitment and retention campaigns, BBK has worked with eight of the top 10 pharmaceutical companies in Japan, since opening its original Japan office in Osaka. The company’s recruitment and engagement software solutions, consulting services and integrated cloud-based infrastructure supports proactive contingency action planning through access to real-time recruitment data tracking and management, and offers critical interfaces for referral management and enrollment reporting for Japan audiences.
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.